Business Context and Reporting Period
This Form 8-K Current Report was filed by Illumina, Inc. on September 5, 2023, with the earliest event reported on August 7, 2023. The filing addresses the departure of a senior executive and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the separation package for the departing officer:
- Base Salary Payment: One year of annual base salary totaling $600,000.
- Health Benefits: Group health insurance premiums under COBRA for 12 months.
- Additional Benefits: Access to certain executive physical benefits during the 2023 calendar year.
Material Changes
The primary material change reported is the departure of Phil Febbo, Chief Medical Officer, effective August 7, 2023. A Separation Agreement was executed on September 5, 2023, formalizing the terms of his exit.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of general corporate risks. The document notes that the full Separation Agreement will be filed as an exhibit to the Company's quarterly report on Form 10-Q for the period ending October 1, 2023.
Key Facts for Investor Verification
- Verify the total cost of the separation package against the company's quarterly expense reports.
- Confirm the appointment of a permanent replacement for the Chief Medical Officer role.
- Review the upcoming Form 10-Q for the full text of the Separation Agreement and any additional terms.
- Note that Charles Dadswell is serving as Interim Chief Executive Officer, General Counsel, and Secretary at the time of signing.